Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease

Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection

(2013) Manjinder Singh et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-β secretion via deregulated lysosomal exocytosis

(2013) Ida Annunziata et al.   Nature Communications

Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease

(2013) Scott J Webster et al.   Alzheimers Research & Therapy

Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease

(2012) Hongxing Wang et al.   BEHAVIOURAL BRAIN RESEARCH

Investigating the binding interactions of galantamine with β-amyloid peptide

(2012) Praveen P.N. Rao et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

(2012) Varsha Shukla et al.   FASEB JOURNAL

Alzheimer's Disease, Oestrogen and Mitochondria: an Ambiguous Relationship

(2012) Amandine Grimm et al.   MOLECULAR NEUROBIOLOGY

Accelerated cortical atrophy in cognitively normal elderly with high  -amyloid deposition

(2012) G. Chetelat et al.   NEUROLOGY

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD)

(2012) R. Lalonde et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Weight loss and Alzheimer's disease: temporal and aetiologic connections

(2012) Giuseppe Sergi et al.   PROCEEDINGS OF THE NUTRITION SOCIETY

Galantamine and behavior in Alzheimer disease: analysis of four trials

(2011) S. Kavanagh et al.   ACTA NEUROLOGICA SCANDINAVICA

Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease

(2011) Chuanyu Li et al.   Current Alzheimer Research

Combination Therapy for Alzheimerʼs Disease

(2011) Laxeshkumar Patel et al.   DRUGS & AGING

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease

(2011) Sergey Kalinin et al.   NEUROBIOLOGY OF AGING

Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting

(2011) Åsa Wallin et al.   Neuropsychiatric Disease and Treatment

Amyloid-β associated cortical thinning in clinically normal elderly

(2010) J. Alex Becker et al.   ANNALS OF NEUROLOGY

Galantamine for Alzheimer's disease

(2010) David Prvulovic et al.   Expert Opinion on Drug Metabolism & Toxicology

Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease

(2010) Oliver Wirths et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors

(2010) Kazuyuki Takata et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain

(2010) T.M. Wengenack et al.   NEUROIMAGE

Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy

(2009) Alfred Maelicke et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Galantamine inhibits β-amyloid aggregation and cytotoxicity

(2009) Balpreet Matharu et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

COL25A1 triggers and promotes Alzheimer’s disease-like pathology in vivo

(2009) Ying Tong et al.   NEUROGENETICS

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

(2008) Stephan Schilling et al.   NATURE MEDICINE

Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model

(2008) Ryoichi Kimura et al.   NEUROBIOLOGY OF DISEASE